In preclinical models, CXB significantly inhibited tumor proliferation in head and neck squamous cell carcinoma (Yip-Schneider et al. 2001), and in OSCC cells in-vitro (Shin et al. 2013). CXB inhibited FOXM1, a transcription factor that controls OSCC development and promotes angiogenesis, invasion, and metastasis (Lam et al. 2013). A 5-week CXB treatment significantly reduced OSCC tumor growth in a murine xenograft model, reversing EMT progression biomarkers like Snail suppression and cadherin switch initiation (Yang et al. 2006). This evidence concerns the gene FOXM1 and head and neck squamous cell carcinoma.